Literature DB >> 24585553

Aortic arch surgery in octogenarians: is it justified?

Hiroshi Kurazumi1, Akihito Mikamo2, Tomoaki Kudo1, Ryo Suzuki1, Masaya Takahashi1, Bungo Shirasawa1, Nobuya Zempo3, Kimikazu Hamano1.   

Abstract

OBJECTIVES: Elderly patients are sometimes denied aortic arch surgery because of the perception of poor outcomes and an unacceptable quality of life (QOL). In this study, we evaluated the early clinical outcomes, long-term survival and QOL following surgical treatment for aortic arch disease in octogenarian patients.
METHODS: A total of 47 consecutive patients over the age of 80 years were referred to our institutions. Of these patients, 20 underwent surgical intervention (surgical group) and 27 were treated medically (medical group). Kaplan-Meier survival analysis was performed between the two groups, and the results were compared with age-matched population data. The risk factors for mortality were determined using a Cox regression analysis. A QOL assessment was performed using the 36-item Short Form Health Survey.
RESULTS: The patient characteristics at baseline were not significantly different between the two groups. In the surgical cases, conventional total aortic arch replacement was performed in 15 patients, debranched thoracic endovascular aortic repair (TEVAR) in 2 and chimney TEVAR in 3. Emergency procedures were performed in 3 patients. No hospital deaths occurred in the surgical groups. Reoperation for bleeding was required in 2 patients, and prolonged mechanical ventilation was required in 4 patients. The 5-year survival was 61.5% in the surgical group and 14.2% in the medical group (P = 0.02). Freedom from aorta-related death at 5 years was 92.3% in the surgical group and 32.3% in the medical group (P = 0.01). There were no differences in the 5-year survival between patients undergoing surgical intervention and the sex- and age-matched population (P = 0.80), whereas the 5-year survival was significantly lower in patients who received medical therapy relative to the sex- and age-matched population (P < 0.001). Medical therapy was the sole risk factor for mortality (hazard ratio: 3.16, P = 0.04). Among the survivors at mid-term, the quality-of-life measures were similar between those in the surgical group and those in the medical group.
CONCLUSIONS: Surgical intervention for aortic arch disease in octogenarians can yield satisfactory early clinical outcomes and acceptable mid-term survival with adequate daily activity. This study indicates that among octogenarians, age alone should not disqualify a patient from receiving an aortic arch intervention.
© The Author 2014. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Entities:  

Keywords:  Aortic arch disease; Octogenarians; Total arch replacement

Mesh:

Year:  2014        PMID: 24585553     DOI: 10.1093/ejcts/ezu056

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  3 in total

1.  Early Efficacy of In Situ Fenestration with a Triple Chimney Technique for High-Risk Stanford Type A Aortic Dissection: A Single-Center Retrospective Study.

Authors:  Qingsong Wu; Heng Lu; Debin Jiang; Zhihuang Qiu; Javed Rashid; Linfeng Xie; Yue Shen; Liangwan Chen
Journal:  J Interv Cardiol       Date:  2021-08-13       Impact factor: 2.279

2.  Total arch replacement versus debranching thoracic endovascular aortic repair for aortic arch aneurysm: what indicates a high-risk patient for arch repair in octogenarians?

Authors:  Yoshimasa Seike; Hitoshi Matsuda; Tetsuya Fukuda; Yosuke Inoue; Atsushi Omura; Kyokun Uehara; Hiroaki Sasaki; Junjiro Kobayashi
Journal:  Gen Thorac Cardiovasc Surg       Date:  2018-01-31

3.  Debranching thoracic endovascular aortic repair for distal aortic arch aneurysm in elderly patients aged over 75 years old.

Authors:  Suguru Shiraya; Yoshinobu Nakamura; Shingo Harada; Yuichiro Kishimoto; Takeshi Onohara; Yuki Otsuki; Tomohiro Kurashiki; Hiromu Horie; Motonobu Nishimura
Journal:  J Cardiothorac Surg       Date:  2020-01-10       Impact factor: 1.637

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.